DOCSLIB.ORG

Download (15MB)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download (15MB) Rodgers, David T. (2013) Investigation of the therapeutic potential of ES- 62 in a murine model of SLE. PhD thesis. http://theses.gla.ac.uk/4771/ Copyright and moral rights for this thesis are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the Author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the Author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Glasgow Theses Service http://theses.gla.ac.uk/ [email protected] Investigation of the therapeutic potential of ES-62 in a murine model of SLE David T. Rodgers B.Sc. M.Res. Ph.D A thesis submitted in fulfillment of the requirements for the degree of Doctor of Philosophy The Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow. Copyright David T. Rodgers September 2013 Abstract Autoimmune inflammatory disorders such as systemic lupus erythematosus (SLE) remain debilitating conditions, as many patients are refractory to existing conventional and biologic therapies or suffer serious adverse effects, such as susceptibility to catastrophic infection. Therapies based on the actions of parasite- derived immunomodulators that dampen inflammation to promote the survival of the parasite without seriously immunocompromising the host, may therefore provide alternative strategies for the development of novel and safer drugs. One such molecule, ES-62, protects against disease in mouse models of rheumatoid arthritis and asthma; in both of these pathologies, suppression of disease is due to modulation of pathogenic IL-17A responses. As IL-17A has been implicated in the pathogenesis of SLE, in this thesis, the therapeutic potential of ES-62 is explored in the MRL/lpr mouse model of SLE. SLE is characterized by autoantibody responses to dsDNA, as well as other nuclear and cytoplasmic antigens, which result in the deposition of autoantibody- immune complexes that cause localized inflammation in tissues with dense capillary networks, most often the skin, joints and kidneys. The MRL/lpr mouse is genetically predisposed to develop lupus-like pathology displaying many of the characteristics of human disease, including the major cause of morbidity, glomerulonephritis. Twice weekly treatment of MRL/lpr mice with ES-62 significantly suppressed the development of proteinuria, a direct measure of renal dysfunction. Despite drastic improvement in renal function, the kidneys from ES-62 treated mice did not show substantial improvement in histopathology as indicated by the overall levels of glomeruloproliferation, cellular infiltration and complement or immunoglobulin deposition in the kidneys. However, exposure to ES-62 did reduce the expression of complement (C3aR and C5aR) and immunoglobulin receptors (FcγRI (CD64)), thus rendering renal cells hypo-responsive to these pro- inflammatory stimuli. Moreover, by modulating MyD88 signaling, ES-62 likely suppresses renal cell responsiveness to chronic DAMP and IL-1 signals as well as potentially promoting glomerular barrier stability. ! ii! Consistent with their hypo-responsive phenotype, renal fibroblasts from ES-62 treated mice produced less MCP-1 in response to TLR stimulation and this was associated with reduced infiltration into the kidney by effector T and B cells and granulocytes; along with the ability of the parasite product to modulate the production of the pro-inflammatory cytokines IL-17A and IL-22. ES-62 suppressed the production of IL-22 both prior to and following onset of disease suggesting a key role for this cytokine in lupus pathogenesis, a proposal confirmed by neutralization studies which demonstrated that IL-22 played an essential role in the development of disease in the MRL/lpr mouse. This was further supported by studies showing that recombinant IL-22 significantly accelerated and exacerbated disease. By contrast, despite suppressing early IL-17A responses, the production of IL-17A was significantly increased in ES-62 treated mice during the established phase of disease, suggesting that IL-17A may promote pathogenesis during the initiation of pathology, yet act to resolve aberrant inflammation in the kidney. This potential dual role for IL-17A in the regulation of kidney inflammation was corroborated by studies using neutralizing antibodies and recombinant IL-17A, as the early neutralization of IL-17A production slowed the onset and severity of proteinuria and the late administration of rIL-17A suppressed disease severity. Aberrant B cell responses drive pathogenesis both in murine models of SLE and also in human disease: reflecting this, B cell depleting therapies have proved successful in the clinic. Thus, the effects of ES-62 on the population dynamics of effector and regulatory B cell subsets were investigated and these studies revealed that ES-62 induced a hypo-responsive B cell phenotype that was associated with modulated development, migration and/or activation of pathogenic effector B cells. Furthermore, the proportion of IL-10 producing ‘regulatory’ B cells were significantly elevated in the ES-62 treated MRL/lpr mice during the established phase of disease. Crucially, the protection afforded against the development of proteinuria by ES-62 was mimicked by the adoptive transfer of B cells from ES-62 treated MRL/lpr mice: moreover, such protection was associated with modulation of the IL-17A/IL-22 axis, as observed in MRL/lpr mice treated with ES-62. ! iii! Together with previous reports on the therapeutic potential of ES-62 in arthritis and asthma, these studies suggest that therapies based on the parasite product have a future in the clinic. ES-62 itself is not suitable as a therapy, due to it immunogenic nature and the complexity of its biosynthesis: thus small molecular analogues (SMAs) of the parasite product have been synthesized. Two of these were tested in the MRL/lpr mouse and found to suppress the development of proteinuria, even when administered after the onset of pathology. This protection, as with that afforded by ES-62, was associated with a modulation of MyD88 signaling in the kidney and indicates that novel drugs, based on the safe modulation of the immune system by the parasite derived product, ES-62, have the potential to treat lupus nephritis in SLE patients. ! iv! Author’s declaration The work presented in this thesis represents the original work carried out by the author and has not been submitted in any form to another university. Where use has been made of materials provided by others, due acknowledgement has been made. Dr. David T. Rodgers B.sc M.Res Ph.D University of Glasgow September 2013 ! v! To the late nighters and weekend writers, keep fighting the good fight. ! vi! Acknowledgements First and foremost, I would like to thank my supervisor, Professor Maggie Harnett: you have been such an inspiration to work with that I feel honored to have learned my trade in your lab. I think the character and spirit of the Harnett lab at Glasgow has been, and continues to be, extremely warm and welcoming; this permeation over the years can only be a testament to the positive support and guidance that you have selflessly provided. Furthermore, I would like to thank Professor Billy Harnett for additional scientific support, mentoring, sharing a beer and taking my jokes whenever Liverpool beat Manchester United. It has been great getting to know you both and working with you over the past 4 years, I look forward to our future collaborations. My heartfelt thanks and gratitude go to the members of the Harnett labs, both old and new, who have made me feel welcome and appreciated for the entirety of my time in the lab. I’ve enjoyed my time with you in Glasgow and look forward seeing you all in the future. I would particularly like to thank those of you who have been closest to me over the years (Miguel, Rusty, Dim, Verica and Jen) as well as those non-Harnetts that have been there all the way (Vuk, Laura and Sharon) our trips to the hills, the pub and Newcastle have kept me sane over the years; although the latter may have made the rest of you insane! Special thanks has to go to the University of Glasgow for hosting he, and to the Wellcome Trust for providing an exceptional program that has allowed to me experience life and science in this great city, not to forget the summer working in the South of France. Furthermore, I would like to thank the trust for funding my scientific travel to the dull destinations of Whistler and Hawai; and for supporting my bench work, which has kept me occupied and off the streets for the past 4 years. On the topic of bench work, I would like to thank some of the most important members of the lab that are often overlooked in acknowledgements, I can’t list you all but I have to mention the Ranin electronic pipettes: without you, I couldn’t have done it. On a more serious note, there are people in the department that have provided support and technical assistance over the years: mainly Jim, Shauna, Robin and Dianne in the GBRC. I would also like to thank Tony, Sandra, Joanne and Denis at the CRF for looking after the lads. I would like to thank my family and friends, with special thanks to parents and sister, for providing me with support and inspiration; I would be nowhere today without their abiding love, dedication and tolerance of my disappearance into the world of science for weeks on end and for always phoning when the football or Strictly is on.
Load more

Recommended publications
  • B-Cell Reconstitution Recapitulates B-Cell Lymphopoiesis Following Haploidentical BM Transplantation and Post-Transplant CY
    Bone Marrow Transplantation (2015) 50, 317–319 © 2015 Macmillan Publishers Limited All rights reserved 0268-3369/15 www.nature.com/bmt LETTER TO THE EDITOR B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY Bone Marrow Transplantation (2015) 50, 317–319; doi:10.1038/ From week 9, the proportion of transitional B cells progressively bmt.2014.266; published online 24 November 2014 decreased (not shown), whereas that of mature B cells increased (Figure 1d). To further evaluate the differentiation of mature cells, we included markers of naivety (IgM and IgD) and memory (IgG) in The treatment of many hematological diseases benefits from our polychromatic panel. At week 9, when a sufficient proportion myeloablative or non-myeloablative conditioning regimens of cells were available for the analysis, B cells were mostly naive followed by SCT or BMT. HLA-matched donors are preferred but and remained so for 26 weeks after haploBMT (Figure 1d). Despite not always available. Instead, haploidentical donors can be rapidly low, the proportion of memory B cells reached levels similar to identified. Unmanipulated haploidentical BMT (haploBMT) with that of marrow donors (Supplementary Figure 1D). non-myeloablative conditioning and post-transplant Cy has been To further investigate the steps of B-cell maturation, we developed to provide a universal source of BM donors.1 Cy, analyzed CD5, a regulator of B-cell activation, and CD21, a which depletes proliferating/allogeneic cells, prevents GVHD.1 component of the B-cell coreceptor complex, on transitional B Importantly, the infection-related mortality was remarkably low, cells. These surface markers characterize different stages of 5,6 5,6 suggesting effective immune reconstitution.1,2 However, a transitional B-cell development.
    [Show full text]
  • B Cell Subsets in Autoimmune Disease B Cell Subsetsb Cell in Autoimmune Disease
    Thesis for doctoral degree (Ph.D.) 2018 Thesis for doctoral degree (Ph.D.) 2018 (Ph.D.) degree doctoral Thesis for B cell subsets in autoimmune disease B cell subsets in autoimmune disease B cell in autoimmune subsets Katrin Habir Katrin Habir From DEPARTMENT OF MEDICINE Karolinska Institutet, Stockholm, Sweden B CELL SUBSETS IN AUTOIMMUNE DISEASE Katrin Habir Stockholm 2018 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Printed by Eprint AB 2018 © Katrin Habir, 2018 ISBN 978-91-7676-900-3 B CELL SUBSETS IN AUTOIMMUNE DISEASE THESIS FOR DOCTORAL DEGREE (Ph.D.) AKADEMISK AVHANDLING som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras i CMM Lecture Hall, L8:00, Center for Molecular Medicine (CMM), Karolinska Universitetssjukhuset, Solna. Friday February 2nd 2018 at 09.00 by Katrin Habir Principal Supervisor: Opponent: Dr. Stephen Malin Associate Professor Bengt Johansson Lindbom Karolinska Institutet Lunds Universitet Department of Medicine Department of Experimental Medical Science Division of Cardiovascular Medicine Division of Adaptive Immunity Co-supervisors: Examination Board: Professor Gunilla Karlsson Hedestam Professor Birgitta Heyman Karolinska Institutet Uppsala Universitet Department of Microbiology, Tumor and Cell Department of Medical Biochemistry and Biology Microbiology Division of Microbiology-Immunology Professor Dan Grandér Karolinska Institutet Associate Professor Lisa Westerberg Department of Oncology-Pathology Karolinska Institutet Department of Microbiology, Tumor and Cell Biology Associate Professor Angela Silveira Karolinska Institutet Department of Medicine Division of Cardiovascular Medicine “We still do not know one thousandth of one percent of what nature has revealed to us.” Albert Einstein THIS THESIS IS DEDICATED TO MY BELOVED ONES ABSTRACT B lymphocytes are a type of white blood cells, belonging to the adaptive arm of the immune system and involved in creating immunological memory.
    [Show full text]
  • Self-Reactive B Cells in the GALT Are Actively Curtailed to Prevent Gut Inflammation
    Self-reactive B cells in the GALT are actively curtailed to prevent gut inflammation Ashima Shukla, … , John R. Apgar, Robert C. Rickert JCI Insight. 2019;4(16):e130621. https://doi.org/10.1172/jci.insight.130621. Research Article Immunology Inflammation Immune homeostasis in the gut-associated lymphoid tissues (GALT) is critical to prevent the development of inadvertent pathologies. B cells, as the producers of antibodies and cytokines, play an important role in maintaining the GALT homeostasis. However, the mechanism by which B cells specifically direct their responses toward non-self-antigens and become ignorant to self-antigens in the GALT is not known. Therefore, we developed what we believe to be a novel mouse model by expressing duck egg lysozyme (DEL) in gut epithelial cells in presence of HEL-reactive B cells. Notably, we observed a transient activation and rapid deletion of self-reactive B cells in Peyer’s patches and mesenteric lymph nodes upon self-antigen exposure. The survival of self-reactive B cells upon exposure to their self-antigen was partially rescued by blocking receptor editing but could be completely rescued by stronger survival signal, such as ectopic expression of BCL2. Importantly, rescuing the self-reactive B cells promoted production of autoantibodies and gut inflammation. Mechanistically, we identify a specific activation of TGF-β signaling in self-reactive B cells in the gut and a critical role of this pathway in maintaining peripheral tolerance. Collectively, our studies describe functional consequences and the fate of self-reactive B cells in GALT and provide potentially novel mechanistic insights governing self-tolerance of B cells in the gut.
    [Show full text]
  • The Pathogenic Role of Innate Lymphoid Cells in Autoimmune-Related and Inflammatory Skin Diseases
    Cellular & Molecular Immunology www.nature.com/cmi REVIEW ARTICLE The pathogenic role of innate lymphoid cells in autoimmune-related and inflammatory skin diseases Suqing Zhou 1, Qianwen Li1, Haijing Wu1 and Qianjin Lu1 Innate lymphoid cells (ILCs), as an important component of the innate immune system, arise from a common lymphoid progenitor and are located in mucosal barriers and various tissues, including the intestine, skin, lung, and adipose tissue. ILCs are heterogeneous subsets of lymphocytes that have emerging roles in orchestrating immune response and contribute to maintain metabolic homeostasis and regulate tissue inflammation. Currently, more details about the pathways for the development and differentiation of ILCs have largely been elucidated, and cytokine secretion and downstream immune cell responses in disease pathogenesis have been reported. Recent research has identified that several distinct subsets of ILCs at skin barriers are involved in the complex regulatory network in local immunity, potentiating adaptive immunity and the inflammatory response. Of note, additional studies that assess the effects of ILCs are required to better define how ILCs regulate their development and functions and how they interact with other immune cells in autoimmune-related and inflammatory skin disorders. In this review, we will distill recent research progress in ILC biology, abnormal functions and potential pathogenic mechanisms in autoimmune-related skin diseases, including systemic lupus erythematosus (SLE), scleroderma and inflammatory diseases, as well as psoriasis and atopic dermatitis (AD), thereby giving a comprehensive review of the diversity and plasticity of ILCs and their unique functions in disease conditions with the aim to provide new insights into molecular diagnosis and suggest potential value in immunotherapy.
    [Show full text]
  • Transitional B Cells in Early Human B Cell Development – Time to Revisit the Paradigm?
    ORIGINAL RESEARCH published: 02 December 2016 doi: 10.3389/fimmu.2016.00546 Transitional B Cells in Early Human B Cell Development – Time to Revisit the Paradigm? Victoria G. Martin1†, Yu-Chang Bryan Wu2†, Catherine L. Townsend1, Grace H. C. Lu2, Joselli Silva O’Hare3, Alexander Mozeika4, Anthonius C. C. Coolen4, David Kipling5, Franca Fraternali2,4 and Deborah K. Dunn-Walters1,3* 1 Division of Infection, Immunity and Inflammatory Disease, Faculty of Life Sciences & Medicine, King’s College London, London, UK, 2 Randall Division of Cell and Molecular Biophysics, Faculty of Life Sciences & Medicine, King’s College London, Edited by: London, UK, 3 Faculty of Health and Medical Sciences, School of Biosciences and Medicine, University of Surrey, Guildford, Ana María Hernández, Surrey, UK, 4 Faculty of Life Sciences & Medicine, Institute for Mathematical and Molecular Biomedicine, King’s College Center of Molecular Immunology, London, London, UK, 5 Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK Cuba Reviewed by: The B cell repertoire is generated in the adult bone marrow by an ordered series of gene Tam Quach, Feinstein Institute for Medical rearrangement processes that result in massive diversity of immunoglobulin (Ig) genes Research, USA and consequently an equally large number of potential specificities for antigen. As the Harry W. Schroeder, process is essentially random, the cells exhibiting excess reactivity with self-antigens are University of Alabama at Birmingham, USA generated and need to be removed from the repertoire before the cells are fully mature. *Correspondence: Some of the cells are deleted, and some will undergo receptor editing to see if changing Deborah K.
    [Show full text]
  • Cd1d Regulates B Cell Development but Not B Cell Accumulation and IL10 Production in Mice with Pathologic CD5+ B Cell Expansion Victoria L
    Palmer et al. BMC Immunology (2015) 16:66 DOI 10.1186/s12865-015-0130-z RESEARCH ARTICLE Open Access Cd1d regulates B cell development but not B cell accumulation and IL10 production in mice with pathologic CD5+ B cell expansion Victoria L. Palmer, Vincent K. Nganga, Mary E. Rothermund, Greg A. Perry and Patrick C. Swanson* Abstract Background: CD1d is a widely expressed lipid antigen presenting molecule required for CD1d-restricted invariant natural killer T (iNKT) cell development. Elevated CD1d expression is detected in CD5+ IL10-producing B cells, called B10 B cells, and is correlated with poorer prognosis in chronic lymphocytic leukemia (CLL), a CD5+ B cell malignancy with B10-like functional properties. Whether CD1d expression regulates CD5+ B cell accumulation, IL10 competence, and antibody production in naïve mice with pathologic CD5+ B cell expansion remains untested. Results: Using three different transgenic mouse models of benign or leukemic CD5+ Bcellexpansion,wefoundthat CD1d was differentially expressed on CD5+ B cells between the three models, but loss of CD1d expression had no effect on CD5+ B cell abundance or inducible IL10 expression in any of the models. Interestingly, in the CLL-prone Eμ-TCL1 model, loss of CD1d expression suppressed spontaneous IgG (but not IgM) production, whereas in the dnRAG1xEμ-TCL1 (DTG) model of accelerated CLL, loss of CD1d expression was associated with elevated numbers of splenic CD4+ and CD8+ T cells and an inverted CD4+:CD8+ T cell ratio. Unexpectedly, before leukemia onset, all three transgenic CD1d-deficient mouse strains had fewer splenic transitional B cells than their CD1d-proficient counterparts.
    [Show full text]
  • High-Dimensional Flow-Cytometric Analysis of Human B-Cell Populations
    High-dimensional flow-cytometric analysis of human B-cell populations The BD FACSCelesta™ cell analyzer and FlowJo™ software together enable deep analysis of B-cell biology Features B-cell development is a stepwise process initiated in the fetal • High-resolution analysis of over 7 distinct liver and postnatal bone marrow and continued in the peripheral B-cell subsets using a 12-color panel lymphoid organs upon encounter with antigens. The various stages of B-cell differentiation can be identified by evaluating • Evaluation of distinct B-cell populations across different tissue types the expression and levels of distinct cell-surface markers, which are regulated throughout the course of B-cell differentiation. • Robust data analysis using the t-SNE analysis feature of FlowJo™ v10 software Multicolor flow cytometry is a powerful tool that has driven key discoveries in B-cell biology by facilitating the investigation of B-cell markers during cell development, differentiation and pathologies such as immunodeficiency, autoimmune disorders and malignancies. This datasheet describes a 12-color flow cytometry panel for the analysis of the most prominent B-cell subsets in human peripheral blood and bone marrow. The 12-color panel included markers uniquely expressed in certain cell subsets such as CD138 in plasma cells, as well as co-expressed markers (CD38 and CD24) (Figure 1A). The panel was designed to identify immature/transitional subsets (T1, T2 and T3), naive B cells, memory B-cell subsets, plasmablasts and plasma cells. The cells in the naive B-cell subset that uniquely express the ATP-binding cassette B1 (ABCB1) transporter were identified by analysis of cell extrusion of MitoTracker™ Green FM (ThermoFisher), a green-fluorescent mitochondrial stain.
    [Show full text]
  • Transitional B Cells Involved in Autoimmunity and Their Impact On
    Zhou et al. J Transl Med (2020) 18:131 https://doi.org/10.1186/s12967-020-02289-w Journal of Translational Medicine REVIEW Open Access Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases Yang Zhou1†, Ying Zhang1†, Jinming Han1, Mengge Yang1, Jie Zhu1,2 and Tao Jin1* Abstract Transitional B cells (TrB cells) represent a crucial link between immature B cells in the bone marrow and mature peripheral B cells. Although TrB cells represent one of the regulatory B cell subpopulations in healthy individuals, the frequency of CD24hiCD38hi TrB cells in circulation may be altered in individuals with autoimmune diseases, such as multiple sclerosis, neuromyelitisoptica spectrum disorders, systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, systemic sclerosis, and juvenile dermatomyositis. Although TrB cells play regulatory roles under infammatory conditions, consequences of their functional impairment vary across autoimmune diseases. Since the origin, development, and function of TrB cells, especially in humans, remain unclear and controversial, this review aimed to discuss the characteristics of TrB cells at steady state and explore their role in various immune diseases, including autoimmune rheumatic diseases and neuroimmunological diseases. Keywords: Transitional B cells, TrB-associated molecules, Autoimmune rheumatic diseases, Multiple sclerosis, Neuromyelitisoptica spectrum disorders Introduction as immature transitional B cells, where they eventually B cells are centrally involved in the pathogenesis of auto- develop into mature B cells [4, 5]. However, in humans, immunity, exerting diverse efects such as contribut- the maturation of TrB cells may not be restricted to the ing to T cell activation through antibody production spleen [5]. TrB cells account for approximately 4% of all and antigen presentation.
    [Show full text]
  • Characterization of Human T-Bet-Expressing B Lymphocytes and Their Role in the Hiv Immune Response
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2017 Characterization Of Human T-Bet-Expressing B Lymphocytes And Their Role In The Hiv Immune Response James Knox University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Allergy and Immunology Commons, Cell Biology Commons, Immunology and Infectious Disease Commons, Medical Immunology Commons, and the Microbiology Commons Recommended Citation Knox, James, "Characterization Of Human T-Bet-Expressing B Lymphocytes And Their Role In The Hiv Immune Response" (2017). Publicly Accessible Penn Dissertations. 2742. https://repository.upenn.edu/edissertations/2742 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2742 For more information, please contact [email protected]. Characterization Of Human T-Bet-Expressing B Lymphocytes And Their Role In The Hiv Immune Response Abstract Humoral immunity is critical for the prevention and control of viral infections, yet the specific B cells and mechanisms regulating antiviral responses in humans remain poorly defined. The Th1-associated transcription factor T-bet coordinates intracellular pathogen immune responses, and recent murine studies identified a -bet-exprT essing B cell subset that mediates humoral antiviral immunity, but an analogous cell population has not been identified in humans. In this study, we sought to investigate the role of T-bet-expressing B cells during human viral infections. We identified -betT expression within the memory B cell compartment of healthy individuals and described a relationship between the transcription factor and IgG1 and IgG3, two antiviral antibody isotypes. The T-bet+ B cell population was comprised of two discrete subsets: T-bet low resting memory cells and a highly activated, transcriptionally distinct T-bet high subset displaying an atypical memory phenotype.
    [Show full text]
  • An Overview of B Cells – from Discovery to Therapy Mini Review
    An Overview of B Cells – from Discovery to Therapy Mini Review Immunology In the past two decades, significant advances have been made in B cell biology. These critical immune cells remain an active area of research particularly because disruption of B cell development or function results in a number of autoimmune diseases and malignancies. In addition to producing antibodies, B cells are professional antigen presenting cells that can present antigens to T cells to generate effective immune responses. B cells are however, a heterogeneous population of cells at different stages of maturation along the lineage, each with unique functional properties. This mini-review provides a brief history of the discovery of B cells, as well as describes the characteristics of each B cell lineage and the processes of B cell development, maturation and activation. Finally, we highlight the application of B cell biology in the development of novel therapeutics for the treatment of B cell mediated diseases. Contents 1. A brief history of the discovery of B cells 2. B cell development and maturation 3. B cell activation and the humoral immune response 4. B cells as therapeutic targets 1. A brief history of the discovery of B cells B cells are an integral part of the adaptive immune response. They represent a distinct lineage, with separate and unique functions from T cells. In addition to producing antibodies, they perform critical immune functions such as generating immunological memory, antigen presentation and regulatory cytokine production. Our current understanding of B cell biology was initiated in 1965 with a landmark study by Max Cooper and Robert Good.
    [Show full text]
  • PI3Kδ Hyper-Activation Promotes Development of B Cells That
    ARTICLE DOI: 10.1038/s41467-018-05674-8 OPEN PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner Anne-Katrien Stark 1,2, Anita Chandra1,2,3,4, Krishnendu Chakraborty1,3, Rafeah Alam1, Valentina Carbonaro1, Jonathan Clark5, Srividya Sriskantharajah6, Glyn Bradley7, Alex G. Richter8,9, Edward Banham-Hall1,3,4, Menna R. Clatworthy10, Sergey Nejentsev3, J. Nicole Hamblin6, Edith M. Hessel6, Alison M. Condliffe11 & Klaus Okkenhaug 1,2 1234567890():,; Streptococcus pneumoniae is a major cause of pneumonia and a leading cause of death world- wide. Antibody-mediated immune responses can confer protection against repeated expo- sure to S. pneumoniae, yet vaccines offer only partial protection. Patients with Activated PI3Kδ Syndrome (APDS) are highly susceptible to S. pneumoniae. We generated a conditional knock-in mouse model of this disease and identify a CD19+B220− B cell subset that is induced by PI3Kδ signaling, resides in the lungs, and is correlated with increased suscept- ibility to S. pneumoniae during early phases of infection via an antibody-independent mechanism. We show that an inhaled PI3Kδ inhibitor improves survival rates following S. pneumoniae infection in wild-type mice and in mice with activated PI3Kδ. These results suggest that a subset of B cells in the lung can promote the severity of S. pneumoniae infection, representing a potential therapeutic target. 1 Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge CB21 3AT, UK. 2 Division of Immunology, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK. 3 Department of Medicine, University of Cambridge, Cambridge CB2 OQQ, UK.
    [Show full text]
  • Molecular Regulation of Peripheral B Cells and Their Progeny in Immunity
    Downloaded from genesdev.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Molecular regulation of peripheral B cells and their progeny in immunity Mark R. Boothby,1,2 Emily Hodges,3 and James W. Thomas1,2 1Department of Pathology–Microbiology–Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA; 2Department of Medicine, Rheumatology Division, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA; 3Department of Biochemistry, Vanderbilt Genetics Institute, Nashville, Tennessee 37232, USA Mature B lymphocytes are crucial components of adap- potentials. A vast trove of findings illuminates the tran- tive immunity, a system essential for the evolutionary fit- scriptional regulation and chromatin modifications (for ness of mammals. Adaptive lymphocyte function requires convenience, referred to here as epigenetic) that program an initially naïve cell to proliferate extensively and its developmental progression from common lymphoid pro- progeny to have the capacity to assume a variety of fates. genitors (CLPs) to the establishment of the naïve popu- These include either terminal differentiation (the long- lations of mature T and B cells (e.g., for review, see lived plasma cell) or metastable transcriptional repro- Busslinger 2004; Champhekar et al. 2015). Similarly, the gramming (germinal center and memory B cells). In this process of diversifying subsets of T cells after their activa- review, we focus principally on the regulation of differen- tion has been studied and reviewed intensively (Glimcher tiation and functional diversification of the “B2” subset. and Murphy 2000; Fang and Zhu 2017; Henning et al. An overview is combined with an account of more recent 2018). Mature B lymphocytes also have the potential to advances, including initial work on mechanisms that distribute their progeny among several distinct fates or eliminate DNA methylation and potential links between intermediate states after they have encountered a ligand intracellular metabolites and chromatin editing.
    [Show full text]